The new ruling reverses a jury verdict from four years ago that handed ArcherDx, which no longer exists, $4.7 million in damages.

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage test.

ArteraAI Prostate is authorized for use as a tool to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.